Skip to main content
Equibles

Yannis Morel

Analyst

Scientist

Equibles does not estimate personal net worth.

About Yannis Morel

Yannis Morel is recorded as Analyst at Scientist. Yannis Morel has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Innate Pharma SA on May 13, 2026. The companies whose calls Yannis Morel spoke on are classified in the Healthcare sector.

Yannis Morel on recent calls

“IPH4502 is our novel and differentiated Nectin-4-Exatecan ADC, which is in Phase 1. Turning to slide 11, IPH4502 has been designed to overcome the limitation of the first-generation Nectin-4 ADCs and to deliver a more favorable therapeutic profile across multiple solid tumors.”
Earnings conference call (announced in 6-K) ·
“On va commencer par vous exposer le rationnel scientifique et les éléments de différenciation technologique qu'il y a derrière nos activités sur les ADC, donc en anglais les antibodies conjugate, en français les conjugués anticorps médicaments.”
Individual shareholders meeting ·

Affiliation history

  • Scientist

    Analyst

    Source not stated

    Current

Company network

Recent activity